In Vivo Evaluation of Candidate Allele-specific Mutant Huntingtin Gene Silencing Antisense Oligonucleotides
Amber L. Southwell(University of Central Florida), Michael R. Hayden(University of British Columbia), Yuanyun Xie(University of British Columbia), Erika B. Villanueva(University of British Columbia), Jeffrey B. Carroll(Western Washington University), Michael E. Østergaard(Ionis Pharmaceuticals (United States)), Crystal N. Doty(University of British Columbia), Holly Kordasiewicz(Ionis Pharmaceuticals (United States)), Niels H. Skotte(University of British Columbia), Kuljeet Vaid(University of British Columbia), Eugenia Petoukhov(University of British Columbia), Punit P. Seth(Ionis Pharmaceuticals (United States)), Clarence Frank Bennett(Ionis Pharmaceuticals (United States)), Andrew T. Watt(University of British Columbia), Susan M. Freier(Ionis Pharmaceuticals (United States)), Eric E. Swayze(Ionis Pharmaceuticals (United States))
Cited by 148
Related Papers
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
|Cell Metabolism|2006|2.1k
Huntington disease
|Nature Reviews Disease Primers|2015|1.6k
Mutations in HFE2 cause iron overload in chromosome 1q–linked juvenile hemochromatosis
|Nature Genetics|2003|976